Skip to Content
Skip to Content

Ainete hindamine - ühenduse hindamisplaan

Ainete hindamine - ühenduse hindamisplaan

For each substance, the table shows the evaluating Member State, the year of evaluation and a short description of the concern which led to it being placed on the list.

Community rolling action plan (CoRAP): The community rolling action plan covers three consecutive years and is updated mid of March every year. From this it follows that substances in the table below with the column ‘Year’ indicating a current or future year, are those that have been prioritised for evaluation, and are effectively on the current CoRAP.

Documents to do with substance evaluation are also available here. They include: documents justifying selection of the substances, decisions to request more information. Member States' conclusions and Member States' final evaluation reports are included for substances for which evaluation has been finalised.

 

Notes to the Substance Evaluation and CoRAP table
  • Where two Members States are indicated, this is a joint evaluation. The first Member State mentioned leads the Evaluation and is the responsible competent authority in the meaning of Article 45(2) of REACH.
  • The substance public name is used. In most of the cases it is the name as disseminated on the ECHA website.
  • When the EC Number is not available, the number assigned to substance by ECHA after the inquiry process is used.
  • When the substances are included in the CoRAP, they have not yet been evaluated and thus the concern is indicative and not exhaustive or conclusive.
  • Contact details of the evaluating Member States are provided for all the substance included.
  • Please note that the justification document explains the grounds of the initial concerns that triggered the inclusion of the substance in the CoRAP for further clarification under substance evaluation. The justification document is based on a preliminary screening of the substance and is without prejudice to the outcome of the substance evaluation.

Legend:

  • Suspected PBT/vPvB: Potentially Persistent, Bioaccumulative and Toxic/very Persistent and very Bioaccumulative.
  • CMR: generic term for known carcinogenic and/or mutagenic and/or reprotoxic properties (according to CLP harmonised or registrant self-classification or CLP Inventory). The concern can refer to C, M, R or a combination of those.
  • Suspected CMR: generic term for suspected carcinogenic and/or mutagenic and/or reprotoxic properties (not classified according to CLP harmonised or registrant self-classification). The concern can refer to (suspected) C, M, R or a combination of those.
  • Sensitiser: generic term for known sensitising properties (according to CLP harmonised or registrant self-classification or CLP Inventory).
  • Suspected sensitiser: generic term for suspected sensitising properties (not classified according to CLP harmonised or registrant self-classification).
  • RCR: Risk Characterisation Ratio
Last updated 26 november 2019. Database contains 375 unique substances/entries.
Filter the list
Initial grounds for concern:

 
247-660-8
26401-35-4
2013
Spain
Suspected PBT/vPvB
High (aggregated) tonnage
Other exposure/risk based concern
Wide dispersive use
Concluded
Details
248-948-6
28299-41-4
2014
Netherlands
Suspected PBT/vPvB
High (aggregated) tonnage
Follow-up
Details
287-401-6
85507-79-5
2014
Denmark
Suspected CMR
High (aggregated) tonnage
Other exposure/risk based concern
Ongoing
Details
211-063-0
628-96-6
2016
Italy
Suspected Reprotoxic
Potential endocrine disruptor
Suspected PBT/vPvB
Suspected Sensitiser
High (aggregated) tonnage
Wide dispersive use
Follow-up
Details
931-274-8
-
2014
Slovenia
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
204-127-4
116-15-4
2015
Italy
Suspected CMR
High (aggregated) tonnage
Ongoing
Details
250-610-8
31394-54-4
2012
Latvia
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
203-571-6
108-31-6
2013
Austria
Sensitiser
High (aggregated) tonnage
High RCR
Concluded
Details
221-375-9
3081-14-9
2012
Belgium
Suspected PBT/vPvB
High (aggregated) tonnage
Concluded
Details
1 - 2.5 moles ethoxylated
500-209-1
68412-54-4
2016
United Kingdom
Potential endocrine disruptor
Other hazard based concern
High (aggregated) tonnage
Concluded
Details
228-250-8
6197-30-4
2012
France
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Follow-up
Details
700-960-7
-
2012
Denmark
Potential endocrine disruptor
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Ongoing
Details
907-745-9
-
2015
Belgium
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Ongoing
Details
203-585-2
108-46-3
2019
France
Potential endocrine disruptor
High (aggregated) tonnage
Ongoing
Details
231-131-3
7440-22-4
2014
Netherlands
Other hazard based concern
High (aggregated) tonnage
Other exposure/risk based concern
Wide dispersive use
Concluded
Details
203-570-0
108-30-5
2013
Austria
Suspected CMR
Sensitiser
High (aggregated) tonnage
High RCR
Concluded
Details
216-653-1
1634-04-4
2014
France
Potential endocrine disruptor
High (aggregated) tonnage
Wide dispersive use
Information requested
Details
205-286-2
137-26-8
2014
Sweden
Potential endocrine disruptor
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
222-182-2
3380-34-5
2012
Netherlands
Potential endocrine disruptor
Suspected PBT/vPvB
High (aggregated) tonnage
Information requested
Details
222-020-0
3319-31-1
2012
Austria
Suspected PBT/vPvB
High (aggregated) tonnage
Wide dispersive use
Ongoing
Details
809-930-9
1330-78-5
2014
Netherlands
Suspected PBT/vPvB
Other hazard based concern
High (aggregated) tonnage
Wide dispersive use
Information requested
Details
231-944-3
7779-90-0
2013
Romania
High (aggregated) tonnage
Wide dispersive use
Concluded
Details
201-222-2
79-74-3
2014
Italy
Suspected PBT/vPvB
High RCR
Follow-up
Details
200-657-5
67-51-6
2020
Spain
Reprotoxic
High RCR
Not started
Details
405-040-6
63500-71-0
2012
Spain
High RCR
Wide dispersive use
Concluded
Details
211-745-8
693-21-0
2016
Italy
Suspected Carcinogenic
Suspected Reprotoxic
Potential endocrine disruptor
Suspected PBT/vPvB
High RCR
Conclusion under preparation
Details
205-288-3
137-30-4
2012
Denmark
Potential endocrine disruptor
High RCR
Information requested
Details
218-645-3
2210-79-9
2016
Denmark
Mutagenic
Information requested
Details
405-520-5
95235-30-6
2021
Belgium
Potential endocrine disruptor
Other exposure/risk based concern
Not started
Details
231-150-7
7440-41-7
2013
Germany
Other exposure/risk based concern
Concluded
Details
206-354-4
330-54-1
2014
Finland
Potential endocrine disruptor
Other exposure/risk based concern
Wide dispersive use
Ongoing
Details
This entry covers synthetic amorphous silicon dioxide as a nanomaterial in the form of stable aggregated particles of particle size > 1 μm, with primary particles of nanosize
231-545-4
7631-86-9
2012
Netherlands
Other hazard based concern
Other exposure/risk based concern
Information requested
Details
931-292-6
308062-28-4
2020
Ireland
Suspected Reprotoxic
Other hazard based concern
Not started
Details
429-320-2
24748-23-0
2019
Netherlands
PBT/vPvB
Ongoing
Details
229-962-1
6864-37-5
2015
Germany
Potential endocrine disruptor
Ongoing
Details
627-872-0
1514-82-5
2019
Spain
Suspected Reprotoxic
Potential endocrine disruptor
Ongoing
Details
248-227-6
27107-89-7
2021
Netherlands
Potential endocrine disruptor
Not started
Details
204-263-4
118-60-5
2020
Germany
Potential endocrine disruptor
Not started
Details
432-520-2
232938-43-1
2020
Belgium
Suspected Reprotoxic
Potential endocrine disruptor
Not started
Details
204-327-1
119-47-1
2016
Denmark
Suspected Reprotoxic
Potential endocrine disruptor
Concluded
Details
251-020-3
32388-55-9
2021
Netherlands
Potential endocrine disruptor
Suspected PBT/vPvB
Not started
Details
204-262-9
118-58-1
2020
Germany
Potential endocrine disruptor
Not started
Details
201-248-4
80-08-0
2016
Germany
Potential endocrine disruptor
Concluded
Details
204-399-4
120-47-8
2021
Germany
Potential endocrine disruptor
Not started
Details
500-006-8
9003-36-5
2020
Denmark
Potential endocrine disruptor
Not started
Details
310-154-3
121158-58-5
2018
Germany
Potential endocrine disruptor
Concluded
Details
219-006-1
2312-35-8
2019
Netherlands
Potential endocrine disruptor
Suspected PBT/vPvB
Ongoing
Details
202-924-1
101-20-2
2019
France
Suspected Reprotoxic
Potential endocrine disruptor
Wide dispersive use
Ongoing
Details
237-159-2
13674-87-8
2020
Germany
Potential endocrine disruptor
Not started
Details
253-057-0
36483-57-5
2021
Denmark
Suspected Carcinogenic
Suspected Mutagenic
Not started
Details

Export search results to:

Categories Display

Märgistatud:

(sisu otsimiseks klõpsake sildil)


Route: .live1